Targets › ATPF0
1 program from 1 company in 1 trial: 1 Phase 3; Infectious disease; next expected readout Aug 2030.
Open in Phaseline: the race on ATPF0, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Assistance Publique - Hôpitaux de Paris | Bedaquiline ATP synthase inhibitor | ATPF0 | Phase 3 | MDR-TB | Aug 2030 |
MDR-TB (1)
small molecule (1)
Assistance Publique - Hôpitaux de Paris (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.